Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Antonioli

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Cellular & Molecular Immunology|May 9, 2020
NKG2A and COVID-19: another brick in the wallLuca Antonioli, Matteo Fornai, Carolina Pellegrini, et al.
Frontiers in Immunology|October 27, 2023
Editorial: Adenosine pathways in cancer immunity and immunotherapyJunjiang Fu, Luca Antonioli, Ali H El-Far
Pharmacological Reviews|June 26, 2019
The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory DiseasesLuca Antonioli, Corrado Blandizzi, Pál Pacher, et al.
Nature Reviews. Cancer|November 15, 2013
Immunity, inflammation and cancer: a leading role for adenosineLuca Antonioli, Corrado Blandizzi, Pál Pacher, et al.
Frontiers in Pharmacology|November 19, 2024
JAK inhibitors: an evidence-based choice of the most appropriate moleculeLuca Antonioli, Alessandro Armuzzi, Massimo C Fantini, et al.
Frontiers in Pharmacology|December 24, 2021
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in InflammasomeCarolina Pellegrini, Luca Antonioli, Gloria Lopez-Castejon, et al.
Inflammatory Bowel Diseases|November 13, 2025
The Importance of Treatment Timing and Positioning in IBDGiulia Valdiserra, Massimo C Fantini, Agnese Favale, et al.
Trends in Molecular Medicine|April 23, 2013
CD39 and CD73 in immunity and inflammationLuca Antonioli, Pál Pacher, E Sylvester Vizi, et al.
Trends in Immunology|January 7, 2019
Rethinking Communication in the Immune System: The Quorum Sensing ConceptLuca Antonioli, Corrado Blandizzi, Pál Pacher, et al.
Frontiers in Pharmacology|May 7, 2020
Editorial: IBD Management-Novel Targets and Therapeutic PerspectivesLuca Antonioli, Matteo Fornai, Barbara Romano, et al.
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Cellular & Molecular Immunology|May 9, 2020
NKG2A and COVID-19: another brick in the wallLuca Antonioli, Matteo Fornai, Carolina Pellegrini, et al.
Frontiers in Immunology|October 27, 2023
Editorial: Adenosine pathways in cancer immunity and immunotherapyJunjiang Fu, Luca Antonioli, Ali H El-Far
Pharmacological Reviews|June 26, 2019
The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory DiseasesLuca Antonioli, Corrado Blandizzi, Pál Pacher, et al.
Nature Reviews. Cancer|November 15, 2013
Immunity, inflammation and cancer: a leading role for adenosineLuca Antonioli, Corrado Blandizzi, Pál Pacher, et al.
Frontiers in Pharmacology|November 19, 2024
JAK inhibitors: an evidence-based choice of the most appropriate moleculeLuca Antonioli, Alessandro Armuzzi, Massimo C Fantini, et al.
Frontiers in Pharmacology|December 24, 2021
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in InflammasomeCarolina Pellegrini, Luca Antonioli, Gloria Lopez-Castejon, et al.
Inflammatory Bowel Diseases|November 13, 2025
The Importance of Treatment Timing and Positioning in IBDGiulia Valdiserra, Massimo C Fantini, Agnese Favale, et al.
Trends in Molecular Medicine|April 23, 2013
CD39 and CD73 in immunity and inflammationLuca Antonioli, Pál Pacher, E Sylvester Vizi, et al.
Trends in Immunology|January 7, 2019
Rethinking Communication in the Immune System: The Quorum Sensing ConceptLuca Antonioli, Corrado Blandizzi, Pál Pacher, et al.
Frontiers in Pharmacology|May 7, 2020
Editorial: IBD Management-Novel Targets and Therapeutic PerspectivesLuca Antonioli, Matteo Fornai, Barbara Romano, et al.
Pageof 18